These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 3927723)

  • 1. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria.
    Thornsberry C
    Am J Med; 1985 Aug; 79(2A):14-20. PubMed ID: 3927723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of first, second and third generation cephalosporins.
    Forsgren A
    Acta Pathol Microbiol Scand B; 1981 Aug; 89(4):221-5. PubMed ID: 6274143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.
    Hall WH; Opfer BJ; Gerding DN
    Antimicrob Agents Chemother; 1980 Feb; 17(2):273-9. PubMed ID: 6247970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activities of third-generation cephalosporins.
    Fass RJ
    Arch Intern Med; 1983 Sep; 143(9):1743-5. PubMed ID: 6615095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.
    Corser CA; Day GJ; Humble MW
    N Z Med J; 1982 Jun; 95(710):414-6. PubMed ID: 6810246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.
    Jones RN; Fuchs PC; Barry AL; Gavan TL; Gerlach EH; Sommers HM
    Clin Ther; 1980; 3(Spec Issue):14-23. PubMed ID: 6446389
    [No Abstract]   [Full Text] [Related]  

  • 8. Third-generation and investigational cephalosporins: II. Microbiologic review and clinical summaries.
    Garzone P; Lyon J; Yu VL
    Drug Intell Clin Pharm; 1983 Sep; 17(9):615-22. PubMed ID: 6311502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.
    Jones RN; Fuchs PC; Sommers HM; Gavan TL; Barry AL; Gerlach EH
    Antimicrob Agents Chemother; 1980 Apr; 17(4):750-6. PubMed ID: 6446880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro antibacterial activity of eight third generation cephalosporins (author's transl)].
    Deforges L; Le Van Thoi J; Soussy CJ; Duval J
    Pathol Biol (Paris); 1982 Jun; 30(6):363-9. PubMed ID: 6810282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of beta-lactam and aminoglycoside antibiotics. A comparative study of 20 parenterally administered drugs.
    Fass RJ
    Arch Intern Med; 1980 Jun; 140(6):763-8. PubMed ID: 7387270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains].
    Mascellino MT; Prignano G; Iegri F; Lorenzi A
    Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity of five cephalosporins.
    Mutton KJ; Harkness JL
    Pathology; 1981 Jan; 13(1):73-7. PubMed ID: 6784093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
    Giamarellou H
    Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in-vitro activity of ceftazidime against clinically important pathogens.
    Knothe H; Dette GA
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():33-41. PubMed ID: 19810167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of blood isolates to various antibiotics, in particular to cephalosporins.
    Ling J; Chau PY; Leung YK; Ng WS
    J Antimicrob Chemother; 1983 May; 11(5):473-80. PubMed ID: 6874632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.